LONDON, Oct. 7, 2015 /PRNewswire/ --
US demand to increase 6.1% annually through 2019
US demand for pharmaceutical chemicals is forecast to rise 6.1 percent annually to $54 billion in 2019. Merchant market sales primarily to generic drug companies will account for nearly one-third of this total. The remainder of demand will consist of the value of pharmaceutical chemicals produced captively or con¬tracted for internal use by makers of proprietary drugs.
New therapies to drive captive & contract market
Although moderated by patent losses, the value of pharmaceutical chemicals obtained from captive and contract production systems will sustain favorable growth, expanding 5.3 percent annually to $36.7 billion in 2019. The introduction of new therapies with enhanced efficacy will underlie gains. For example, in 2014, a total of 41 new molecular entities were approved for marketing by the Food and Drug Administration. Among these approvals were several breakthrough therapies, including blinatumomab for acute lymphoblastic leukemia, ceritinib for late-stage non-small cell lung cancer, ledipasvir/sofosbuvir for chronic hepatitis C, nintedanib and pirfenidone for idiopathic pulmonary fibrosis, and nivolumab for metastatic melanoma. In addition to new molecular entities, growth prospects for proprietary pharma¬ceutical chemicals will benefit from a number of recent prescription to over-the-counter switches, which extended commercial protection on non-prescrip¬tion versions of compounds such as esomeprazole magnesium and fluticasone proprionate.
Merchant market demand to grow nearly 8% per annum
Based on the impact of recent and forth-coming drug patent expirations and the expansion of the generic drug industry, merchant market demand for pharmaceu¬tical chemicals will increase 7.8 percent per year to $17.3 billion in 2019. Gains will reflect the introduction and rapid market penetration of generic versions of several blockbuster drugs. Among the pharmaceutical chemicals projected to generate impressive growth in merchant sales due to patent expirations are aripi-prazole for bipolar disorder; capecitabine for metastatic breast and colorectal cancer; celecoxib for arthritis; duloxitine HCl for depression, generalized anxiety, and chronic pain; eszopiclone for insomnia; glatiramer acetate for multiple sclerosis; oxycodone HCl for pain management; and raloxifene HCl for osteoporosis.
This upcoming industry study, Pharmaceutical Chemicals, presents historical demand data (2004, 2009, 2014) plus forecasts (2019, 2024) by type of active pharmaceutical ingredient (API) and raw material. The study also considers key market environment factors, assesses the industry structure, evaluates company market share, and profiles 51 participants in the US industry.
Download the full report: https://www.reportbuyer.com/product/3078229/
About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48